Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Orion Oyj is a Finnish pharmaceutical company specializing in proprietary drugs, generic medicines, and active pharmaceutical ingredients (APIs). The company operates primarily in the Nordic region and select European markets, with a strong focus on neurology, oncology, and pain management therapeutics. Orion's competitive position is anchored in its proprietary Parkinson's disease treatments and a vertically integrated manufacturing base in Finland.
Orion generates revenue through a mix of high-margin proprietary drugs protected by patents and regulatory exclusivity, and lower-margin generics leveraging its manufacturing scale. The company's pricing power is strongest in its proprietary neurology portfolio where it has established clinical efficacy and limited competition in specific indications. Vertical integration in API production provides cost advantages and supply chain control. The Nordic market focus offers stable reimbursement environments and predictable demand, though limits addressable market size.
Proprietary drug sales volume and pricing, particularly Parkinson's disease franchise performance in Nordic and European markets
Pipeline progress and regulatory approvals for new molecular entities or line extensions in neurology and oncology
Generic drug pricing pressure in European markets and competitive intensity from larger generic manufacturers
Currency fluctuations (EUR/SEK, EUR/NOK) affecting Nordic revenue translation and purchasing power
Healthcare reimbursement policy changes in Finland, Sweden, and other key markets
Patent cliffs on proprietary drugs as exclusivity periods expire, exposing revenue to generic competition without sufficient pipeline replacement
Healthcare cost containment pressures across European markets driving reimbursement cuts and mandatory price reductions for both branded and generic drugs
Regulatory complexity and lengthening approval timelines for new drugs in EU markets, increasing R&D costs and time-to-market
Biosimilar competition emerging in oncology supportive care, potentially eroding margins in established product lines
Large multinational pharmaceutical companies (Novartis, Roche, Pfizer) with deeper R&D budgets and broader geographic reach competing in neurology and oncology
Generic drug manufacturers (Teva, Sandoz) with greater scale and lower cost structures pressuring generic pharmaceutical margins
Limited geographic diversification concentrated in Nordic/European markets exposes company to regional regulatory and reimbursement risks
R&D investment requirements to maintain proprietary pipeline may pressure free cash flow if late-stage trials fail or regulatory approvals are delayed
Currency exposure to SEK and NOK fluctuations against EUR affects reported revenue and profitability from non-Finnish Nordic operations
low - Pharmaceutical demand is largely non-discretionary and driven by disease prevalence rather than economic cycles. Chronic disease treatments like Parkinson's medications maintain stable demand through recessions. However, generic drug pricing can face pressure during economic downturns as healthcare systems and patients seek cost savings. The 29.7% revenue growth suggests strong underlying demand independent of macro conditions.
Rising interest rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples for growth-oriented pharma stocks, particularly affecting the 5.9x P/S ratio; (2) increased financing costs for working capital and potential M&A, though the low 0.31 debt/equity ratio minimizes this exposure. Pharmaceutical demand itself is rate-insensitive, but investor appetite for healthcare growth stocks diminishes as risk-free rates rise.
Minimal - Orion's strong balance sheet (1.99x current ratio, 0.31 debt/equity) and pharmaceutical business model require limited external financing for operations. The company generates positive operating cash flow ($0.3B) and is not dependent on credit markets for working capital. Healthcare reimbursement systems in Nordic countries provide reliable payment, reducing receivables risk.
growth - The 29.7% revenue growth, 52.2% net income growth, and 62.3% one-year return attract growth-oriented investors seeking exposure to specialty pharmaceutical expansion. The 31.2% ROE and strong cash generation also appeal to quality-focused investors. However, the 5.9x P/S and 23.0x EV/EBITDA valuations indicate market expectations for continued above-market growth, requiring sustained pipeline success and proprietary drug performance.
moderate - Pharmaceutical stocks typically exhibit moderate volatility driven by binary clinical trial outcomes, regulatory decisions, and patent expiration events rather than daily economic data. The -2.9% recent drawdown after a 62.3% annual gain suggests profit-taking rather than fundamental deterioration. Mid-cap pharma stocks ($11.1B market cap) have higher volatility than large-cap peers but lower than small-cap biotech.
